Literature DB >> 11273726

Stage-specific differential activation of mitogen-activated protein kinases in hypertrophied and failing rat hearts.

W Hayashida1, Y Kihara, A Yasaka, K Inagaki, Y Iwanaga, S Sasayama.   

Abstract

Mitogen-activated protein kinases (MAPKs) are involved in the early development of cardiac hypertrophy, but their roles in chronic left ventricular hypertrophy (LVH) are unclear. We studied the angiotensin (Ang) II-induced cardiac MAPK activation of the hypertensive Dahl salt-sensitive (DS) rats in the subacute developing LVH stage, the chronic compensated LVH stage, and the congestive heart failure (CHF) stage. In the isolated, coronary-perfused heart preparation, Ang II infusion (1x10(-6)mol/l) activated extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38-MAPK in the LV myocardium. No substantial differences were observed in the Ang II-induced ERK activation between the normotensive control DS rats and the hypertensive DS rats in either stage. In contrast, the Ang II-induced activation of JNK and p38-MAPK was augmented in the subacute LVH stage of the hypertensive DS rats, but then progressively attenuated in the chronic LVH and CHF stages. Chronic treatment with an angiotensin converting enzyme inhibitor, temocapril (20 mg/kg/day), ameliorated the responsiveness of the JNK/p38-MAPK activation, suggesting that the decreased JNK/p38-MAPK activation is a consequence of negative feedback regulation for the activated cardiac renin-angiotensin system in chronic LVH and CHF. Thus, the Ang II-induced activation of multiple cardiac MAPK pathways are differentially regulated, depending on the stages of chronic hypertrophic process. The JNK and p38-MAPK activation may be involved in the early development of adaptive LVH. However, the responsiveness of the cardiac JNK/p38-MAPK pathways progressively decreased in chronic LVH and CHF under the chronic activation of tissue renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11273726     DOI: 10.1006/jmcc.2001.1341

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  14 in total

1.  High sodium augments angiotensin II-induced vascular smooth muscle cell proliferation through the ERK 1/2-dependent pathway.

Authors:  Gang Liu; Hirofumi Hitomi; Asadur Rahman; Daisuke Nakano; Hirohito Mori; Tsutomu Masaki; Hong Ma; Takahiro Iwamoto; Hiroyuki Kobori; Akira Nishiyama
Journal:  Hypertens Res       Date:  2013-09-12       Impact factor: 3.872

2.  Young Scholars Award Lecture: Intratubular angiotensinogen in hypertension and kidney diseases.

Authors:  Hiroyuki Kobori; Yuri Ozawa; Yuki Suzaki; Minolfa C Prieto-Carrasquero; Akira Nishiyama; Tatsuya Shoji; Eric P Cohen; L Gabriel Navar
Journal:  Am J Hypertens       Date:  2006-05       Impact factor: 2.689

3.  Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet.

Authors:  Hiroyuki Kobori; Akira Nishiyama; Youichi Abe; L Gabriel Navar
Journal:  Hypertension       Date:  2003-02-10       Impact factor: 10.190

Review 4.  Statins and the myocardium.

Authors:  Seema Mital; James K Liao
Journal:  Semin Vasc Med       Date:  2004-11

Review 5.  Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology.

Authors:  Tána Ravingerová; Miroslav Barancík; Monika Strnisková
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

6.  Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27.

Authors:  Rudolf A de Boer; Saraswati Pokharel; Markus Flesch; Derk A van Kampen; Albert J H Suurmeijer; Frans Boomsma; Wiek H van Gilst; Dirk J van Veldhuisen; Yigal M Pinto
Journal:  J Mol Med (Berl)       Date:  2004-08-20       Impact factor: 4.599

7.  Effects of tempol on renal angiotensinogen production in Dahl salt-sensitive rats.

Authors:  Hiroyuki Kobori; Akira Nishiyama
Journal:  Biochem Biophys Res Commun       Date:  2004-03-12       Impact factor: 3.575

Review 8.  Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease.

Authors:  Hiroyuki Kobori; Maki Urushihara
Journal:  Pflugers Arch       Date:  2012-08-24       Impact factor: 3.657

Review 9.  Angiotensin II blockade and renal protection.

Authors:  Hiroyuki Kobori; Hirohito Mori; Tsutomu Masaki; Akira Nishiyama
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor.

Authors:  Juan C Osorio; Faisal H Cheema; Timothy P Martens; Naila Mahmut; Caroline Kinnear; Ana M D Gonzalez; William Bonney; Shunichi Homma; James K Liao; Seema Mital
Journal:  Can J Physiol Pharmacol       Date:  2008-09       Impact factor: 2.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.